World Health Organization (WHO) projects that the global count of people aged above 65 years, will reach 2 billion by 2050. With the rising geriatric populations, due to several age related conditions, there will be more surgical procedures, which will increase the demand for hemostasis and tissue sealing agents. Hemostasis and tissue sealing agents are used to prevent hemorrhage. During a surgery it is very important to stop the excessive bleeding of the patient, to avoid further damage or death by blood loss. This has created the need for hemostasis and tissue sealing agents. The increasing number of surgeries, introduction of multi-usage and ready-to-use products along with the global rise in geriatric populations supplement the growth of the global hemostasis and tissue sealing agents market during the analysis period. Recently, the FDA has approved numerous hemostatic products that would further drive the growth of global hemostasis and tissue sealing agents market. Factors restraining the market growth are high prices of the products and stringent regulatory environment.

The global hemostasis and tissue sealing agents market, is segmented on the basis of product type and geography. The product types considered, in this report include Topical Hemostats and Adhesive and Tissue Sealing Agents. Topical Hemostats are further classified into Mechanical Hemostats, Active Hemostats, Flowable Hemostats, Fibrin Sealants and Topical Thrombin Products. Adhesive and Tissue Sealing Agents are further classified into Natural Tissue Sealants, Synthetic Tissue Sealants and Adhesion Barrier Products. Geographically, the market is segmented into four regions namely North America, Europe, Asia Pacific and LAMEA. One of the strategies adopted by major market players is product launch. For instance, in 2013, Baxter Launched Hemopatch, which is an Innovative Sealing Hemostat. This easy to use product (has helped the company gain competitiveness in the European market. The companies profiled in this report are Johnson & Johnson, CryoLife, Baxter, Cohera Medical, Omrix Biopharmaceuticals, Advance Medical Solution Group, Entegrion, Cryolife, Bioster and Nycomed.

KEY MARKET BENEFITS:

• The report provides a quantitative analysis of the current market and estimations which would enable the stakeholders to capitalize on prevailing market opportunities
• Extensive analysis of the global apheresis equipment market by product type helps in understanding the types of equipment that are currently used along with the variants that would gain prominence in future
• Competitive intelligence highlights the business practices followed by leading market players across various geographies
• Comprehensive analysis of factors that drive and restrict the growth of the global apheresis equipment market is provided
• SWOT analysis highlights the internal environment of leading companies for effective strategy formulation
• The apheresis equipment market scenario is comprehensively analysed in accordance to the key regions

 Key Market Segments

• By Product Type
  • Topical Hemostats
    • Mechanical Hemostats
    • Active Hemostats
    • Flowable Hemostats
    • Fibrin Sealants
    • Topical Thrombin Products
  • Adhesive and Tissue Sealing Agents
    • Natural Tissue Sealants
    • Synthetic Tissue Sealants
    • Adhesion Barrier Products
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • UAE
    • Rest of LAMEA

 
Key Market Players

• Entegrion
• Johnson & Johnson
• CryoLife
• Nycomed
• Bioster
• Omrix Biopharmaceuticals
• Baxter
• Cohera Medical
• Advance Medical Solution Group

• CHAPTER 1: INTRODUCTION

  • 1.1. Report Description

  • 1.2. Key Market Segments

  • 1.3. Key Benefits

  • 1.4. Research Methodology

    • 1.4.1. Primary Research

    • 1.4.2. Secondary Research

    • 1.4.3. Analyst Tools and Models

• CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

• CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope

  • 3.2. Key Findings

    • 3.2.1. Top Investment Pockets

    • 3.2.2. Top Winning Strategies

  • 3.3. Porter's Five Forces Analysis

    • 3.3.1. Bargaining Power of Suppliers

    • 3.3.2. Threat of New Entrants

    • 3.3.3. Threat of Substitutes

    • 3.3.4. Competitive Rivalry

    • 3.3.5. Bargaining Power among Buyers

  • 3.5. Market Dynamics

    • 3.5.1. Drivers

    • 3.5.2. Restraints

    • 3.5.3. Opportunities

• CHAPTER 4: HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview

    • 4.1.1 Market Size and Forecast, By Product Type

  • 4.2. Topical Hemostats

    • 4.2.1. Key Market Trends, Growth Factors and Opportunities

    • 4.2.2. Market Size and Forecast, By Region

    • 4.2.3. Market Share Analysis, By Country

    • 4.2.4. Mechanical Hemostats

      • 4.2.4.1. Market Size and Forecast

    • 4.2.4. Active Hemostats

      • 4.2.4.1. Market Size and Forecast

    • 4.2.4. Flowable Hemostats

      • 4.2.4.1. Market Size and Forecast

    • 4.2.4. Fibrin Sealants

      • 4.2.4.1. Market Size and Forecast

    • 4.2.4. Topical Thrombin Products

      • 4.2.4.1. Market Size and Forecast

  • 4.3. Adhesive And Tissue Sealing Agents

    • 4.3.1. Key Market Trends, Growth Factors and Opportunities

    • 4.3.2. Market Size and Forecast, By Region

    • 4.3.3. Market Share Analysis, By Country

    • 4.3.4. Natural Tissue Sealants

      • 4.3.4.1. Market Size and Forecast

    • 4.3.4. Synthetic Tissue Sealants

      • 4.3.4.1. Market Size and Forecast

    • 4.3.4. Adhesion Barrier Products

      • 4.3.4.1. Market Size and Forecast

• CHAPTER 5: HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY REGION

  • 5.1. Market Overview

    • 5.1.1 Market Size and Forecast, By Region

  • 5.2. North America

    • 5.2.1. Key Market Trends and Opportunities

    • 5.2.2. Market Size and Forecast, By Product Type

    • 5.2.3. Market Size and Forecast, By Country

    • 5.2.4. U.S. Hemostasis And Tissue Sealing Agents Market

      • 5.2.4.1. Market Size and Forecast, By Product Type

    • 5.2.5. Canada Hemostasis And Tissue Sealing Agents Market

      • 5.2.5.1. Market Size and Forecast, By Product Type

    • 5.2.6. Mexico Hemostasis And Tissue Sealing Agents Market

      • 5.2.6.1. Market Size and Forecast, By Product Type

  • 5.3. Europe

    • 5.3.1. Key Market Trends and Opportunities

    • 5.3.2. Market Size and Forecast, By Product Type

    • 5.3.3. Market Size and Forecast, By Country

    • 5.3.4. France Hemostasis And Tissue Sealing Agents Market

      • 5.3.4.1. Market Size and Forecast, By Product Type

    • 5.3.5. Germany Hemostasis And Tissue Sealing Agents Market

      • 5.3.5.1. Market Size and Forecast, By Product Type

    • 5.3.6. Italy Hemostasis And Tissue Sealing Agents Market

      • 5.3.6.1. Market Size and Forecast, By Product Type

    • 5.3.7. Spain Hemostasis And Tissue Sealing Agents Market

      • 5.3.7.1. Market Size and Forecast, By Product Type

    • 5.3.8. UK Hemostasis And Tissue Sealing Agents Market

      • 5.3.8.1. Market Size and Forecast, By Product Type

    • 5.3.9. Russia Hemostasis And Tissue Sealing Agents Market

      • 5.3.9.1. Market Size and Forecast, By Product Type

    • 5.3.10. Rest Of Europe Hemostasis And Tissue Sealing Agents Market

      • 5.3.10.1. Market Size and Forecast, By Product Type

  • 5.4. Asia-Pacific

    • 5.4.1. Key Market Trends and Opportunities

    • 5.4.2. Market Size and Forecast, By Product Type

    • 5.4.3. Market Size and Forecast, By Country

    • 5.4.4. China Hemostasis And Tissue Sealing Agents Market

      • 5.4.4.1. Market Size and Forecast, By Product Type

    • 5.4.5. Japan Hemostasis And Tissue Sealing Agents Market

      • 5.4.5.1. Market Size and Forecast, By Product Type

    • 5.4.6. India Hemostasis And Tissue Sealing Agents Market

      • 5.4.6.1. Market Size and Forecast, By Product Type

    • 5.4.7. South Korea Hemostasis And Tissue Sealing Agents Market

      • 5.4.7.1. Market Size and Forecast, By Product Type

    • 5.4.8. Australia Hemostasis And Tissue Sealing Agents Market

      • 5.4.8.1. Market Size and Forecast, By Product Type

    • 5.4.9. Thailand Hemostasis And Tissue Sealing Agents Market

      • 5.4.9.1. Market Size and Forecast, By Product Type

    • 5.4.10. Malaysia Hemostasis And Tissue Sealing Agents Market

      • 5.4.10.1. Market Size and Forecast, By Product Type

    • 5.4.11. Indonesia Hemostasis And Tissue Sealing Agents Market

      • 5.4.11.1. Market Size and Forecast, By Product Type

    • 5.4.12. Rest of Asia Pacific Hemostasis And Tissue Sealing Agents Market

      • 5.4.12.1. Market Size and Forecast, By Product Type

  • 5.5. LAMEA

    • 5.5.1. Key Market Trends and Opportunities

    • 5.5.2. Market Size and Forecast, By Product Type

    • 5.5.3. Market Size and Forecast, By Country

    • 5.5.4. Brazil Hemostasis And Tissue Sealing Agents Market

      • 5.5.4.1. Market Size and Forecast, By Product Type

    • 5.5.5. South Africa Hemostasis And Tissue Sealing Agents Market

      • 5.5.5.1. Market Size and Forecast, By Product Type

    • 5.5.6. Saudi Arabia Hemostasis And Tissue Sealing Agents Market

      • 5.5.6.1. Market Size and Forecast, By Product Type

    • 5.5.7. UAE Hemostasis And Tissue Sealing Agents Market

      • 5.5.7.1. Market Size and Forecast, By Product Type

    • 5.5.8. Argentina Hemostasis And Tissue Sealing Agents Market

      • 5.5.8.1. Market Size and Forecast, By Product Type

    • 5.5.9. Rest of LAMEA Hemostasis And Tissue Sealing Agents Market

      • 5.5.9.1. Market Size and Forecast, By Product Type

• CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction

  • 6.2. Top Winning Strategies

  • 6.3. Product Mapping Of Top 10 Player

  • 6.4. Competitive Dashboard

  • 6.5. Competitive Heatmap

  • 6.6. Top Player Positioning, 2024

• CHAPTER 7: COMPANY PROFILES

  • 7.1. Johnson And Johnson

    • 7.1.1. Company Overview

    • 7.1.2. Key Executives

    • 7.1.3. Company Snapshot

    • 7.1.4. Operating Business Segments

    • 7.1.5. Product Portfolio

    • 7.1.6. Business Performance

    • 7.1.7. Key Strategic Moves and Developments

  • 7.2. CryoLife

    • 7.2.1. Company Overview

    • 7.2.2. Key Executives

    • 7.2.3. Company Snapshot

    • 7.2.4. Operating Business Segments

    • 7.2.5. Product Portfolio

    • 7.2.6. Business Performance

    • 7.2.7. Key Strategic Moves and Developments

  • 7.3. Baxter

    • 7.3.1. Company Overview

    • 7.3.2. Key Executives

    • 7.3.3. Company Snapshot

    • 7.3.4. Operating Business Segments

    • 7.3.5. Product Portfolio

    • 7.3.6. Business Performance

    • 7.3.7. Key Strategic Moves and Developments

  • 7.4. Cohera Medical

    • 7.4.1. Company Overview

    • 7.4.2. Key Executives

    • 7.4.3. Company Snapshot

    • 7.4.4. Operating Business Segments

    • 7.4.5. Product Portfolio

    • 7.4.6. Business Performance

    • 7.4.7. Key Strategic Moves and Developments

  • 7.5. Omrix Biopharmaceuticals

    • 7.5.1. Company Overview

    • 7.5.2. Key Executives

    • 7.5.3. Company Snapshot

    • 7.5.4. Operating Business Segments

    • 7.5.5. Product Portfolio

    • 7.5.6. Business Performance

    • 7.5.7. Key Strategic Moves and Developments

  • 7.6. Advance Medical Solution Group

    • 7.6.1. Company Overview

    • 7.6.2. Key Executives

    • 7.6.3. Company Snapshot

    • 7.6.4. Operating Business Segments

    • 7.6.5. Product Portfolio

    • 7.6.6. Business Performance

    • 7.6.7. Key Strategic Moves and Developments

  • 7.7. Entegrion

    • 7.7.1. Company Overview

    • 7.7.2. Key Executives

    • 7.7.3. Company Snapshot

    • 7.7.4. Operating Business Segments

    • 7.7.5. Product Portfolio

    • 7.7.6. Business Performance

    • 7.7.7. Key Strategic Moves and Developments

  • 7.8. Bioster

    • 7.8.1. Company Overview

    • 7.8.2. Key Executives

    • 7.8.3. Company Snapshot

    • 7.8.4. Operating Business Segments

    • 7.8.5. Product Portfolio

    • 7.8.6. Business Performance

    • 7.8.7. Key Strategic Moves and Developments

  • 7.9. Nycomed

    • 7.9.1. Company Overview

    • 7.9.2. Key Executives

    • 7.9.3. Company Snapshot

    • 7.9.4. Operating Business Segments

    • 7.9.5. Product Portfolio

    • 7.9.6. Business Performance

    • 7.9.7. Key Strategic Moves and Developments

• LIST OF TABLES

• TABLE 1. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 2. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET FOR TOPICAL HEMOSTATS, BY REGION, 2025-2033 ($MILLION)
• TABLE 3. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET FOR ADHESIVE AND TISSUE SEALING AGENTS, BY REGION, 2025-2033 ($MILLION)
• TABLE 4. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY REGION, 2025-2033 ($MILLION)
• TABLE 5. NORTH AMERICA HEMOSTASIS AND TISSUE SEALING AGENTS, BY REGION, 2025-2033 ($MILLION)
• TABLE 6. NORTH AMERICA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 7. U.S. HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 8. CANADA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 9. MEXICO HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 10. EUROPE HEMOSTASIS AND TISSUE SEALING AGENTS, BY REGION, 2025-2033 ($MILLION)
• TABLE 11. EUROPE HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 12. FRANCE HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 13. GERMANY HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 14. ITALY HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 15. SPAIN HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 16. UK HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 17. RUSSIA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 18. REST OF EUROPE HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 19. ASIA-PACIFIC HEMOSTASIS AND TISSUE SEALING AGENTS, BY REGION, 2025-2033 ($MILLION)
• TABLE 20. ASIA-PACIFIC HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 21. CHINA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 22. JAPAN HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 23. INDIA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 24. SOUTH KOREA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 25. AUSTRALIA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 26. THAILAND HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 27. MALAYSIA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 28. INDONESIA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 29. REST OF ASIA PACIFIC HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 30. LAMEA HEMOSTASIS AND TISSUE SEALING AGENTS, BY REGION, 2025-2033 ($MILLION)
• TABLE 31. LAMEA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 32. BRAZIL HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 33. SOUTH AFRICA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 34. SAUDI ARABIA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 35. UAE HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 36. ARGENTINA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 37. REST OF LAMEA HEMOSTASIS AND TISSUE SEALING AGENTS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
• TABLE 38. JOHNSON AND JOHNSON: KEY EXECUTIVES
• TABLE 39. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
• TABLE 40. JOHNSON AND JOHNSON: OPERATING SEGMENTS
• TABLE 41. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
• TABLE 42. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 43. CRYOLIFE: KEY EXECUTIVES
• TABLE 44. CRYOLIFE: COMPANY SNAPSHOT
• TABLE 45. CRYOLIFE: OPERATING SEGMENTS
• TABLE 46. CRYOLIFE: PRODUCT PORTFOLIO
• TABLE 47. CRYOLIFE: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 48. BAXTER: KEY EXECUTIVES
• TABLE 49. BAXTER: COMPANY SNAPSHOT
• TABLE 50. BAXTER: OPERATING SEGMENTS
• TABLE 51. BAXTER: PRODUCT PORTFOLIO
• TABLE 52. BAXTER: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 53. COHERA MEDICAL: KEY EXECUTIVES
• TABLE 54. COHERA MEDICAL: COMPANY SNAPSHOT
• TABLE 55. COHERA MEDICAL: OPERATING SEGMENTS
• TABLE 56. COHERA MEDICAL: PRODUCT PORTFOLIO
• TABLE 57. COHERA MEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 58. OMRIX BIOPHARMACEUTICALS: KEY EXECUTIVES
• TABLE 59. OMRIX BIOPHARMACEUTICALS: COMPANY SNAPSHOT
• TABLE 60. OMRIX BIOPHARMACEUTICALS: OPERATING SEGMENTS
• TABLE 61. OMRIX BIOPHARMACEUTICALS: PRODUCT PORTFOLIO
• TABLE 62. OMRIX BIOPHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 63. ADVANCE MEDICAL SOLUTION GROUP: KEY EXECUTIVES
• TABLE 64. ADVANCE MEDICAL SOLUTION GROUP: COMPANY SNAPSHOT
• TABLE 65. ADVANCE MEDICAL SOLUTION GROUP: OPERATING SEGMENTS
• TABLE 66. ADVANCE MEDICAL SOLUTION GROUP: PRODUCT PORTFOLIO
• TABLE 67. ADVANCE MEDICAL SOLUTION GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 68. ENTEGRION: KEY EXECUTIVES
• TABLE 69. ENTEGRION: COMPANY SNAPSHOT
• TABLE 70. ENTEGRION: OPERATING SEGMENTS
• TABLE 71. ENTEGRION: PRODUCT PORTFOLIO
• TABLE 72. ENTEGRION: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 73. BIOSTER: KEY EXECUTIVES
• TABLE 74. BIOSTER: COMPANY SNAPSHOT
• TABLE 75. BIOSTER: OPERATING SEGMENTS
• TABLE 76. BIOSTER: PRODUCT PORTFOLIO
• TABLE 77. BIOSTER: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 78. NYCOMED: KEY EXECUTIVES
• TABLE 79. NYCOMED: COMPANY SNAPSHOT
• TABLE 80. NYCOMED: OPERATING SEGMENTS
• TABLE 81. NYCOMED: PRODUCT PORTFOLIO
• TABLE 82. NYCOMED: KEY STRATEGIC MOVES AND DEVELOPMENTS

• LIST OF FIGURES

• FIGURE 1. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET SEGMENTATION
• FIGURE 2. GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET
• FIGURE 3. SEGMENTATION HEMOSTASIS AND TISSUE SEALING AGENTS MARKET
• FIGURE 4. TOP INVESTMENT POCKET IN HEMOSTASIS AND TISSUE SEALING AGENTS MARKET
• FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
• FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
• FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 8. LOW THREAT OF SUBSTITUTION
• FIGURE 9. HIGH COMPETITIVE RIVALRY
• FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHEMOSTASIS AND TISSUE SEALING AGENTS MARKET
• FIGURE 11. HEMOSTASIS AND TISSUE SEALING AGENTS MARKET SEGMENTATION, BY BY PRODUCT TYPE
• FIGURE 12. HEMOSTASIS AND TISSUE SEALING AGENTS MARKET FOR TOPICAL HEMOSTATS, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 13. HEMOSTASIS AND TISSUE SEALING AGENTS MARKET FOR ADHESIVE AND TISSUE SEALING AGENTS, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 14. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
• FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
• FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
• FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 18. COMPETITIVE DASHBOARD
• FIGURE 19. COMPETITIVE HEATMAP: HEMOSTASIS AND TISSUE SEALING AGENTS MARKET
• FIGURE 20. TOP PLAYER POSITIONING, 2024
• FIGURE 21. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
• FIGURE 22. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 23. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 24. CRYOLIFE: NET SALES, 2022-2024 ($MILLION)
• FIGURE 25. CRYOLIFE: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 26. CRYOLIFE: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 27. BAXTER: NET SALES, 2022-2024 ($MILLION)
• FIGURE 28. BAXTER: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 29. BAXTER: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 30. COHERA MEDICAL: NET SALES, 2022-2024 ($MILLION)
• FIGURE 31. COHERA MEDICAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 32. COHERA MEDICAL: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 33. OMRIX BIOPHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
• FIGURE 34. OMRIX BIOPHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 35. OMRIX BIOPHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 36. ADVANCE MEDICAL SOLUTION GROUP: NET SALES, 2022-2024 ($MILLION)
• FIGURE 37. ADVANCE MEDICAL SOLUTION GROUP: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 38. ADVANCE MEDICAL SOLUTION GROUP: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 39. ENTEGRION: NET SALES, 2022-2024 ($MILLION)
• FIGURE 40. ENTEGRION: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 41. ENTEGRION: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 42. BIOSTER: NET SALES, 2022-2024 ($MILLION)
• FIGURE 43. BIOSTER: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 44. BIOSTER: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 45. NYCOMED: NET SALES, 2022-2024 ($MILLION)
• FIGURE 46. NYCOMED: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 47. NYCOMED: REVENUE SHARE, BY REGION, 2024 (%)